Institute of Nanotechnology and Bioengineering, University of Central Lancashire, Preston, PR1 2HE England, UK.
Int J Pharm. 2013 Feb 28;444(1-2):193-9. doi: 10.1016/j.ijpharm.2012.12.040. Epub 2013 Jan 5.
The aerosol properties of niosomes were studied using Aeroneb Pro and Omron MicroAir vibrating-mesh nebulizers and Pari LC Sprint air-jet nebulizer. Proniosomes were prepared by coating sucrose particles with Span 60 (sorbitan monostearate), cholesterol and beclometasone dipropionate (BDP) (1:1:0.1). Nano-sized niosomes were produced by manual shaking of the proniosomes in deionized water followed by sonication (median size 236nm). The entrapment of BDP in proniosome-derived niosomes was higher than that in conventional thin film-made niosomes, being 36.4% and 27.5% respectively. All nebulizers generated aerosols with very high drug output, which was 83.6% using the Aeroneb Pro, 85.5% using the Pari and 72.4% using the Omron. The median droplet size was 3.32μm, 3.06μm and 4.86μm for the Aeroneb Pro, Pari and Omron nebulizers respectively and the "fine particle fraction" (FPF) of BDP was respectively 68.7%, 76.2% and 42.1%. The predicted extrathoracic deposition, based on size distribution of nebulized droplets was negligible for all devices, suggesting all of them are potentially suitable for pulmonary delivery of niosomes. The predicted drug deposition in the alveolar region was low using the Omron (3.2%), but greater using the Aeroneb Pro (17.4%) and the Pari (20.5%). Overall, noisome-BDP aerosols with high drug output and FPF can be generated from proniosomes and delivered using vibrating-mesh or air-jet nebulizers.
采用 Aeroneb Pro、Omron MicroAir 振动网孔和 Pari LC Sprint 空气射流雾化器研究了非诺索体的气溶胶特性。将蔗糖颗粒用 Span 60（山梨糖醇单硬脂酸酯）、胆固醇和丙酸倍氯米松（BDP）（1:1:0.1）包衣制备前体非诺索体。通过手动将前体非诺索体在去离子水中摇晃并随后进行超声处理制备纳米级非诺索体（中值粒径 236nm）。BDP 在前体非诺索体衍生的非诺索体中的包封率高于常规薄膜制备的非诺索体，分别为 36.4%和 27.5%。所有雾化器均产生药物输出率非常高的气溶胶，Aeroneb Pro 为 83.6%，Pari 为 85.5%，Omron 为 72.4%。Aeroneb Pro、Pari 和 Omron 雾化器的中位液滴粒径分别为 3.32μm、3.06μm 和 4.86μm，BDP 的“细颗粒分数”（FPF）分别为 68.7%、76.2%和 42.1%。基于雾化液滴的粒径分布，预测所有装置的胸腔外沉积量可忽略不计，表明它们均适合非诺索体的肺部给药。Omron 装置（3.2%）的肺泡区域药物沉积量较低，而 Aeroneb Pro（17.4%）和 Pari（20.5%）的药物沉积量较高。总体而言，高药物输出率和 FPF 的非诺索体-BDP 气溶胶可从前体非诺索体制备，并使用振动网孔或空气射流雾化器输送。
